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INTRODUCTION
Recent advances in imaging techniques may enable 
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  This paper reports on issues relating to the optimal use of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid 
magnetic resonance imaging (Gd-EOB-DTPA MR imaging) together with the generation of consensus statements from a 
working group meeting, which was held in Seoul, Korea (2010). Gd-EOB-DTPA has been shown to improve the detection and 
characterization of liver lesions, and the information provided by the hepatobiliary phase is proving particularly useful in 
differential diagnoses and in the characterization of small lesions (around 1-1.5 cm). Discussion also focused on advances 
in the role of organic anion-transporting polypeptide 8 (OATP8) transporters. Gd-EOB-DTPA is also emerging as a promising 
tool for functional analysis, enabling the calculation of post-surgical liver function in the remaining segments. Updates to 
current algorithms were also discussed.
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earlier and more accurate diagnosis of hepatocellular 
carcinoma (HCC), with the ultimate aim of improving its 
poor prognosis. To date, HCC is the third most common 
cause of cancer deaths worldwide (1), and the survival 
rate in developing countries is only around 3-5% (2). As 
imaging modalities evolve, so do the potential benefits; for 
example, volumetric (3D) ultrasound (US) could increase 
diagnostic accuracy by enabling a high signal-to-noise 
ratio; contrast-enhanced (Sonazoid® or Sonovue®) US may 
improve vascularity assessment; and dual-energy computed 
tomography (CT) could have potential clinical application 
in non-contrast imaging, including the assessment of liver, 
iron and fat content of biliary stones; whilst perfusion 
CT could differentiate diverse tumor tissue, but the 
radiation dosage needed (10-20 mSV) is likely to limit its Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 404
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applicability. 
The role of contrast-enhanced magnetic resonance 
imaging (CE-MR imaging) with agents such as GD-EOB-
DTPA (Primovist®; Bayer HealthCare, Berlin, Germany) is 
expanding, with this modality being widely viewed as a 
problem-solving tool. The biphasic nature of Gd-EOB-DTPA 
enables dynamic-phase imaging, and as approximately 
50% is taken up by organic anion-transporting polypeptide 
8 (OATP8) (also referred to as OATP1B3) receptors in 
functioning liver hepatocytes, this also enables images 
to be obtained in the hepatobiliary phase (3-8). Gd-EOB-
DTPA MR imaging is a comprehensive liver analysis tool; 
this is largely due to the hepatocellular uptake, subsequent 
biliary excretion and hemodynamic qualities of this 
contrast agent. These features are expected to: improve 
tumor detection and characterization compared with other 
imaging modalities; enable small lesions to be monitored 
over a long-term follow-up period; increase the diagnostic 
accuracy of post-resection liver-related complications, 
and the anatomical and functional information obtained 
from Gd-EOB-DTPA MR imaging can be used for planning 
treatment decisions.
It is also speculated that hepatobiliary agents may 
be used to evaluate the progressive loss of the biliary 
polarization, and the impairment of the microstructure 
of the biliary secretion (9). This, and other pathological 
changes that occur during hepatocarcinogenesis can 
be captured with CE-MR imaging, and it is essential to 
optimize the role of Gd-EOB-DTPA MR imaging in the 
evaluation of this process, particularly during early stages 
of HCC development.
Some of these issues were considered at the  
4th International Forum for Liver MR imaging (Primovist® 
User Meeting), which was held in Seoul, South Korea, 
October 29-30, 2010. Approximately 90 delegates from 
Europe, Asia and the USA attended the meeting; all 
delegates participated in the generation of statements 
on the role of CE-MR imaging and Gd-EOB-DTPA using an 
interactive system. Statements were defined in workgroups 
and those statements that were supported by the majority 
of the delegates are reported in this paper.
Evaluation of Hepatocarcinogenesis with Gd-EOB-DTPA 
MR Imaging: Correlation with Histopathological Findings
The detection and characterization of small HCCs  
(≤ 1.5 cm) is one of the most important, but challenging 
issues in the management of cirrhotic patients. Small 
HCCs can be divided into early HCCs, which have a vaguely 
nodular appearance and are well differentiated, whereas 
progressed HCCs have a distinctly nodular pattern, are 
moderately differentiated with evidence of intra-hepatic 
spread (10, 11). Early HCCs grow more slowly than 
progressed HCCs and have a more favorable outcome both 
in terms of time to recurrence and long-term survival rate 
(12). However, the transition from pre-malignant dysplastic 
nodules (DNs) to early and progressed HCCs can be difficult 
to determine. This transition is heterogeneous; and not all 
nodules display step-wise progression, which may be due to 
variation in the developmental process (13). 
There is evidence to suggest that lesion size can be a 
good indicator of typical multistep development. In a study 
of 980 nodules resected from 664 patients, the incidence of 
multistep hepatocarcinogenesis was 74% in tumors  
≤ 1 cm and was 9% in tumors > 5 cm (14). The transition 
from high-grade DN (HGDN) to early HCC (grade I [little 
cellular atypia]) is supposed to generally occur in lesions 
< 1 cm in size. This transition may be histopathologically 
characterized by the appearance of grade I foci in DN  
(Fig. 1A). Further progression of early HCC to nodule-in-
nodule type HCC (grade II [overt carcinoma nodule in 
early HCC]) may occur in lesions around 1.5 cm, and this 
transition may be initially characterized by grade II foci 
A B
Fig. 1. Image illustrating appearance of grade I foci in dysplastic nodule (A) and grade II foci in early hepatocellular carcinoma (B).Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 405
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appearing in grade I lesions (Fig. 1B). The transformation 
from slow to rapid growing HCCs also occurs in lesions 
around 1.5 cm in size. A follow-up study of 53 nodules has 
shown that the tumor volume doubling time was 13.9 (11.7) 
for early HCC and 6.0 (5.2) months for progressed HCC; 
distribution of lesions based on these data are summarized 
in Figure 2 (15, 16).
Consensus statement: Biopsy or follow-up should be 
considered in small (i.e. 1-1.5 cm) hypointense lesions in 
the hepatobiliary phase of Gd-EOB-DTPA.
Visualization of Early Hepatocellular Carcinoma with Gd-
EOB-DTPA MR Imaging
The use of contrast-enhanced MR imaging with agents 
such as Gd-EOB-DTPA could improve the detectability rate 
of early HCC (in nodules around 1-1.5 cm). In a study of 30 
resected specimens, a low- to slightly low-signal intensity 
in the hepatobiliary phase of Gd-EOB-DTPA MR imaging 
correctly identified 23 of 24 hypovascular hepatocyte 
nodules as early HCCs (only 1 nodule was wrongly identified 
as a DN or a regenerative nodule [RN]). An iso- to high-
signal intensity correctly identified 5 of 6 lesions as a DN or 
RN (only one nodule was wrongly identified as early HCC). 
The detection accuracy was 93% (28 of 30) in this study 
(17). Additional information from histopathological samples   
(i.e. biopsy samples and genetic biomarkers such as HSP70, 
CAP2, GPC3, beta-catenin and p53) (13) could provide 
detailed information about the grade of malignancy for each 
nodule. Taken together, this approach could enable more 
detailed information on patient outcome and treatment 
choice at an early stage.
Consensus statement: The hepatobiliary phase of Gd-EOB-
DTPA reflects early hepatocarcinogenesis.
Organic Anion-Transporting Polypeptide 8 Expression 
and Tumor Differentiation
In addition to tumor size, OATP8 expression could also 
correlate with differentiation and histopathological features 
of liver lesions. OATP8 is a member of the OATP family, 
which transport both intrinsic factors (such as bile acid 
components and hormones) and extrinsic factors (such as 
drugs) throughout the liver, kidney and gastrointestinal 
tract (18). Unlike other members of the family, OATP8 
expression is restricted to the basolateral and lateral 
membrane of human hepatocytes (19). Another member of 
the family, OATP-C also mediates the uptake of amphipathic 
compounds into hepatocytes; this transporter exists on the 
sinusoidal side of hepatocytes.
However, the liver-enriched transcription factor HNF3beta 
has been found to repress the transcription of OATP8, 
but not OATP-C in HCCs; HNF3beta was increased in 70% 
of lesions and correlated inversely with OATP8 mRNA. 
As a result, the expression of OATP8 was decreased by 
60% in the HCC compared with the surrounding normal 
parenchyma, but expression of OATP-C was not significantly 
decreased (20). These findings have been confirmed by 
immunohistochemical staining of 49 HCCs resected from 47 
patients using a primary antibody against human OATP8 (7). 
This was followed by semiquantitative evaluation of OATP8 
intensity. The degree of OATP8 expression was found to 
correlate with tumor differentiation in hypointense HCC (Fig. 3).
Fig. 2. Distribution of lesion type according to size. Most nodules 
may be sub-clinical (i.e. ≤ 5 mm) (15). DN = dysplastic nodule, 
eHCC = early hepatocellular carcinoma, G = grade, HGDN = high-grade 
dysplastic nodule, LGDN = low-grade dysplastic nodule
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Fig. 3. Signal intensity on hepatobiliary phase of Gd-EOB-DTPA-
enhanced MR imaging and expression of OATP8 during multi-step 
hepatocarcinogenesis. eHCC = early hepatocellular carcinoma, HGDN 
= high-grade dysplastic nodule, LGDN = low-grade dysplastic nodule, 
OATP8 = organic anion-transporting polypeptide 8, RN = regenerative 
nodule
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Gd-EOB-DTPA MR Imaging and Organic Anion-Transporting 
Polypeptide 8 Expression in Hepatocellular Carcinoma
Organic anion-transporting polypeptide 8 is the most 
probable uptake transporter for Gd-EOB-DTPA in human 
hepatocytes, and it is likely to be excreted into bile 
secretions by multi-drug resistance proteins (MRP), 
predominantly MRP3 (7, 8, 21). Signal intensity during the 
hepatobiliary phase of Gd-EOB-DTPA is, therefore, likely to 
correlate with expression of these molecular transporters. As 
the degree of OATP8 expression declines during multi-step 
hepatocarcinogenesis according to malignancy grade, there 
will be a decline of enhancement ratio on the hepatobiliary 
phase due to a reduced Gd-EOB-DTPA uptake. Calculation 
of this enhancement ratio could be useful for estimating 
malignancy grade (except in around 5-10% of HCCs, that 
show prominent expression of OATP8, which is probably due 
to genetic alterations). It is also important to note that the 
signal intensity on the hepatobiliary phase of Gd-EOB-DTPA 
differs between hypo- and iso-/hyper-intense HCCs (Fig. 
4); this has also been confirmed by immunostaining. This 
may be due to the fact that hypointense HCCs have lower 
expression of OATP8 (7). 
Diagnosis and Management of Hepatocellular 
Carcinoma in the Cirrhotic Liver 
Role of Contrast-Enhanced MR Imaging 
Use of extracellular contrast media (ECCM) for dynamic 
MR imaging provides sufficient information for confident 
diagnosis of typical enhancing HCC, but for hypovascular 
lesions and mimickers, more information is required. This 
‘gap’ has traditionally been filled by fine needle biopsy 
and immunohistochemical analysis, however, the extra 
information provided by dual contrast agents such as Gd-
EOB-DTPA, with both dynamic and hepatobiliary phase 
imaging (HBPI) characteristics, may allow a more detailed 
and confident diagnosis of cirrhotic liver lesions from one 
MR imaging procedure. Such advances in contrast media 
may have enabled the number of imaging modalities needed 
for a correct diagnosis to be decreased, and this may have 
reduced the need for fine-needle biopsies (22). 
These advances may also be reflected in the changing 
guidelines; the AASLD (2005) guidelines recommended that 
coincidental, conclusive imaging features on two dynamic 
imaging tests were required to make a diagnosis of HCC 
for US-defined nodules of between 1-2 cm diameter (23). 
However, in the updated guidelines, only one dynamic 
imaging test is recommended (either 4-phase multidetector 
computed tomography [MDCT] or CE-MR imaging), and if 
atypical imaging features are present, then both modalities 
can be used (24).
Consensus statement: GD-EOB-MR imaging can be used 
as a first-line tool for the characterization of a new nodule 
that has been detected in cirrhotic liver using US (including 
contrast-enhanced ultrasound [CEUS]. Gd-EOB-MR imaging 
can also replace ECCM MR imaging for this purpose.
Fig. 4. Correlation between tumor enhancement ratio on 
hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging 
and amount of OATP8 expression at polymerase chain reaction. 
Expression score = (tumor transporter value/tumor b-actin 
value)/(background transporter value/background b-actin 
value). Enhancement ratio = (pre-enhancement signal intensity [SI] 
minus post-enhancement SI)/pre-enhancement SI. Reprinted, with 
permission, from Kitao et al. Radiology 2010;256(3):817-826.  
© Radiological Society of North America (7).
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Fig. 5. Dynamic phase of Gd-EOB-DTPA MR imaging (A) shows 
clear arterial enhancement and washout of two hepatocellular 
carcinomas but hepatobiliary phase (B) also shows several 
subcentimeter hypointense nodules confirmed as well-
differentiated, hepatocellular carcinoma.
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Added Value of the Hepatobiliary Phase of Gd-EOB-DTPA
The updated guidelines on HCC detection and diagnosis 
from the Japan Society of Hepatology have include HBPI 
information in their algorithm as a problem-solving tool 
when dynamic MR imaging or CT show atypical vascular 
features (25). The benefits of HBPI include a homogeneous, 
strong and prolonged enhancement of liver parenchyma 
through cellular uptake, resulting in good contrast between 
focal liver lesions and healthy parenchyma. The typical 
enhancement pattern achieved, which is considered the 
hallmark of an HCC, is the presence of arterial enhancement 
followed by washout of the tumor in the portal venous 
and/or delayed phases (26). Data from 55 patients with 
66-pathology confirmed HCCs showed that a diagnosis 
(defined as arterial enhancement plus washout) could be 
established in 65% patients with CT and in 80% with Gd-
EOB-DTPA MR imaging. When hypointensity of nodule on 
HBPI was added to the diagnostic criteria (as most HCCs 
nodules will show this), 83% were diagnosed as HCCs using 
Gd-EOB-DTPA MR imaging (27) (Fig. 5). 
Consensus statement: Gd-EOB-DTPA is an appropriate 
second-line imaging modality as recommended by the 
recent Japanese guidelines.
Contrast-enhanced MR imaging also shows a higher 
sensitivity for HCC detection, especially for nodules < 2 cm 
diameter compared with other imaging modalities (28-30). 
The information provided by the hepatobiliary phase of Gd-
EOB-DTPA MR imaging may increase the diagnostic accuracy 
of small HCC compared with MDCT; the mean sensitivity 
of dynamic and HB images was significantly higher (0.72) 
than dynamic MR images alone (0.63; p = 0.008) or MDCT 
(0.61; p = 0.001) in a sample of 67 HCCs from 36 patients 
(31). HBPI also allows greater differentiation of small 
hypervascular HCCs (≤ 2 cm) from arterially enhancing 
pseudolesions (AEPs) (32, 33). In a study of 69 patients 
with 53 AEPs and 44 HCCS; 95% of HCCs demonstrated low 
signal intensity in the hepatobiliary phase and 94% of AEPs 
showed iso-signal intensity on the hepatobiliary phase (32).
In addition, HBPI may provide information regarding 
hepatocyte function within borderline lesions, therefore, 
offering valuable information regarding multi-step 
hepatocarcinogenesis. In this way, decreased uptake of Gd-
EOB-DTPA may be an indicator of malignant change  
(34, 35). CE-MR imaging may also increase the conspicuity 
and delineation of tumor margins compared with CT, the 
visualization of intra-hepatic vessels, and provide a map 
of multinodular HCCs for planning subsegmental TACE. 
HBPI may also provide additional information for use in 
differential diagnoses (see next section). 
Consensus statement: A hypointense nodule in 
the hepatobiliary phase of Gd-EOB-DTPA that is non-
hypervascular in the arterial phase is regarded as 
intermediate risk whereas one that is hypervascular in the 
arterial phase is high-risk. 
Management of Incidental Liver Lesions
The discovery of liver masses during investigations for 
unrelated clinical problems is increasing, which may, in 
part, be due to the widespread use of advanced imaging 
techniques (36). As management of these incidental lesions 
is taking up increasing amounts of clinical practice it is 
important to gain a confident diagnosis early to reduce 
further investigation time and associated costs. There are 
many diagnostic algorithms for incidental lesions presented 
in the literature, but no existing consensus on the best 
sequence of modalities to use. Imaging must be based on 
the underlying clinical context, diagnostic accuracy, patient 
safety, and cost efficacy (37-39). MR imaging is one of the 
most accurate imaging modalities for differential diagnoses, 
allowing positive identification in 70% of cases (40), and is 
complimentary to other techniques such as CEUS (41). Since 
both vascularity and hepatobiliary uptake add important 
information on the differential diagnosis an algorithm for 
image interpretation based on these imaging findings (along 
with other findings from T2-weighted [T2W] sequences 
and diffusion-weighted imaging [DWI]) is considered 
to be helpful for image interpretation in daily practice. 
However, it should be kept in mind that the wide variety 
of all differential diagnoses cannot be covered in a simple 
algorithm and that atypical image manifestations can be 
seen from time to time.
Consensus statement: The proposed algorithm in Figure 
6 for the work-up of incidental lesions using Gd-EOB-DTPA 
MR imaging in patients without increased risk of HCC is 
appropriate.
Differential Diagnosis in Non-Cirrhotic Liver
The range of lesions observed in the non-cirrhotic liver 
is larger than for cirrhotic organs, from benign masses 
such as focal fatty infiltration or focal nodular hyperplasia 
(FNH) to malignant lesions, including metastases, 
cholangiocarcinomas or HCCs (40). Older age (> 55 years), 
enlarged liver and a raised serum alkaline phosphatase are 
associated with malignancy, but there are no reliable clinical Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 408
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characteristics that can distinguish benign from malignant 
lesions (42). Malignant lesions can appear in patients who 
are otherwise healthy; 11 unexpected malignant lesions 
were found in 64 healthy patients followed-up for five years 
(42). 
Certain radiographic features such as size, distribution, 
and morphology are helpful in distinguishing between 
benign and malignant, but can be unreliable for diagnosis. 
Multiple liver lesions may be indicative of metastases, 
but rare cases of multiple cystic masses, for example, can 
occur. Likewise, single large masses may be indicative of 
hemangioma, but some carcinoma may present a similar 
initial picture. T2W MR images provide better evidence for 
lesion type; signal intensity compared with surrounding 
parenchyma gives a good indication as to the threat of the 
mass. DWI is also an informative tool, with lesion signal 
Fig. 6. Proposed algorithm for work-up of incidental lesions using Gd-EOB-DTPA MR imaging in patients without increased risk of 
HCC. CE-CT = contrast enhanced CT, DWI = diffusion-weighted imaging, FNH = focal nodular hyperplasia, HBP = hepatobiliary phase, HCC = 
hepatocellular carcinoma, T1W = T1-weighted, T2W = T2-weighted, THID = transient hepatic signal intensity differences, US = ultrasound
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into account (fat, hemorrhage)
+ DWI
+ Long echo time in T2W
yes no
no
Incidental liver lesion
(unclear after US or CE-CT)
Gd-EOB-DTPA-
enhanced MR imaging
Unclear Lesion
FNH/THID
STOP
Unclear solid lesion
Hemangioma
STOP
Consider hypervascular
metastasis
Consider adenoma
Consider hypervascular
metastasis or HCC
(in case of cirrhosis)
Consider hypervascular
metastasis or
cholangiocarcinoma or
sclerosed hemangioma (DWI)
or focal fat (in/opp T1W)
Unclear solid lesion
Cyst
Hemangioma
< 5% FNH
Adenoma
Metastases
Focal fat
Lesion strong
hyperintense in T2W?
Hypervascularity 
in arterial phase?
Washout in
venous phase?
Weak or strong
hypointensity
in HBP?
Lesion hyper-
or iso-intense 
in HBP?*
Precontrast and
dynamic phase typical
for FNH (scar)
or THID?
no
yes
no
yes
no
yes
strong
yes
inhomogeneous uptake in HBP
weak
Solid hepatocellular
LesionKorean J Radiol 12(4), Jul/Aug 2011 kjronline.org 409
Consensus Report for Gd-EOB-DTPA MRI
changes between low and high b values being particularly 
important. However, this assessment is less reliable for the 
differential diagnosis within the group of solid lesions than 
for cystic masses or hemangiomas.
Whilst the vascularity and portal venous washout patterns 
of liver lesions remains an essential tool for diagnosis, in 
many cases the added information gained from hepatobiliary 
phase imaging is essential for an accurate diagnosis (as 
shown in Fig. 5), without the need for invasive sampling, 
especially for solid tumors. In this respect, the presence 
of regular hepatocellular uptake helps to classify liver 
lesions and, therefore, represents an important step for 
the characterization of lesions (43). For this reason, the 
evaluation of the signal intensity of an unclear liver mass 
in the hepatobiliary phase might be a valuable approach as 
shown in the proposed algorithm. If regular hepatocellular 
uptake is seen (in line with other typical imaging features), 
than a benign nature of a lesion is very likely.
Differential Diagnosis in Cirrhotic Liver
Common lesions found in cirrhotic liver are hyperplastic 
nodules, DNs, FNH-like nodules, and HCCs, all of which 
tend to show hyperintensity in the hepatobiliary 
phase (44). DNs are usually small (< 1.5 cm diameter), 
homogeneous, isointense on T2W imaging, show no 
arterial hypervascularity, and are hyper- or isointense in 
the hepatobiliary phase. During follow up of these types 
of lesions, any arterial hypervascularity or reduction in 
hepatobiliary phase signal intensity (hypointensity) might 
suggest malignant change.
Focal nodular hyperplasia-like nodules are believed 
to arise as the result of a local hyperplastic response to 
decreased portal venous and increased hepatic arterial 
blood flow. They are not considered premalignant and have 
imaging features similar to classical FNH, but they are seen 
in patients with hepatic vascular abnormalities or chronic 
liver disease. In patients with cirrhosis, FNH-like nodules 
are often difficult to differentiate from well differentiated 
HCCs, due to the arterial phase enhancement, but unlike 
HCCs, they show hyperintensity in the hepatobiliary phase 
with a hypointense central, stellate-like scar. FNH-like 
nodules are also frequently multiple in occurrence and show 
minimal growth during long-term follow-up.
Around 5-10% of HCCs (grade 1-2) appear as hyperintense 
in the hepatobiliary phase of Gd-EOB-DTPA MR imaging. 
These can be differentiated correctly using features of 
HBPI, including heterogeneous uptake of contrast agent, a 
hypointense rim suggestive of a pseudocapsule, and internal 
septation due to differential histological components 
within the lesion. Mimickers of HCC in high-risk patients are 
bile duct adenoma (peribiliary hamartoma), small arterial-
enhancing nodules, and cholangiocarcinoma. Bile duct 
adenoma is a benign, non-cystic, non-encapsulated, small 
(< 2 cm) lesion involving the ductules, inflammation and 
fibrosis. These lesions are thought to be reactive processes 
to focal injury, and may be associated with chronic liver 
disease (45-47). These show hypervascularity and delayed 
enhancement. Small arterially-enhancing lesions can 
be differentiated from small HCCs as they do not show 
hyperintensity on T2W images or a hypointense defect 
on HBPI. However, some very small arterially-enhancing 
lesions (< 1 cm) can show clear portal venous washout and 
hepatobiliary defect. 
Cholangiocarcinoma is a malignant lesion, but should be 
differentiated from HCC as the treatment plans are different 
in many cases. Cholangiocarcinomas are homogeneous, 
with an irregular lobulated margin, and no capsule. The 
periphery usually contains arterially-enhancing viable tumor 
cells, with variable degrees of fibrosis and coagulative 
necrosis in the central lesion. These lesions tend to show 
irregular peripheral and gradual centripetal enhancement, 
with prominent delayed enhancement being common 
on ECCM MR imaging (which may not occur on Gd-EOB-
DTPA MR imaging). Importantly, sclerosing hemangioma 
or tuberculosis in a hepatitis B virus patient can show 
a similar enhancement patterns to cholangiocarcinoma, 
and these lesions may require a histological confirmation 
for diagnosis. Solitary metastases may also be difficult to 
differentiate from cholangiocarcinoma, even on histologic 
examination. However, the presence of central necrosis, 
which is rare in cholangiocarcinoma, indicated by strong 
high signal intensity on T2W images, may favor the 
diagnosis of metastasis.
Consensus statement: In patients without risk of HCC, 
substantial hepatobiliary uptake indicates a benign lesion.
Challenges in Asian Populations
Other challenging diagnoses in the Asian population are 
inflammatory lesions (such as migrating, focal eosinophilic 
lesions) or unexpected HCC in otherwise healthy patients. 
Focal steatosis is an uncommon lesion type that may be 
encountered after a patient has undergone chemotherapy, 
and can appear similar to HCC with fatty changes. 
Consensus statement: Gd-EOB-DTPA MR imaging is Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 410
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considered useful as the next step to characterize a liver 
lesion that is unclear on US or CE-CT.
Pre-Surgical Planning and Post-Surgical Complications: 
the Role of Gd-EOB-DTPA MR Imaging
Discussing patient diagnosis and subsequent treatment 
options within multidisciplinary teams is recognized as an 
optimal approach to patient management (48). A key aim 
of such discussions between surgeons, gastroenterologists, 
oncologists and radiologists is to identify candidates for 
curative interventions - i.e. not to deny treatment to 
patients with potentially curable disease by overstaging, or 
subject patients to futile procedures by understaging.
Using colorectal cancer liver metastases (CRCLM) as an 
example of pre-surgical management - evidence suggest 
that around 50% of patients with colorectal cancer have 
metastases in the liver at the time of diagnosis of the 
primary tumor. Approximately 50% of liver metastases will 
be detected synchronous to the primary tumor, while the 
rest will become detectable later, as metachronous disease 
(49, 50). Operative mortality and morbidity for CRCLM are 
low, resulting in a 5-year survival of 38-55% (49). Failure 
to achieve long-term survival is largely due to the high 
frequency of extra-hepatic recurrence (often in combination 
with intra-hepatic recurrences), which account for about 
two thirds of recurrences (51, 52). The remaining third 
of cases, however, have isolated intra-hepatic recurrence. 
Logically, in some of these patients, higher accuracy 
in the detection of all intra-hepatic disease could have 
resulted in long-term survival with modifications in the 
surgical approach. The limitations of currently available 
imaging modalities (US, CT, conventional MR imaging and 
fluorodeoxyglucose positron emission tomography [FDG-
PET]), in terms of the per patient and per lesion sensitivity, 
especially for lesions in the sub-centimeter range, still 
presents a major problem (53, 54). 
Pre-Surgical Anatomical Assessments
A large range of normal anatomical variations exist 
regarding both the biliary and vascular anatomy of the liver 
(55-58). A summary of the pre-surgery requirements and 
clinical motivation for the information is presented in  
Table 1. Prior to intervention, the surgeon requires 
information regarding the anatomy of the hepatic vascular 
supply and drainage and biliary tree, as well as proximity 
to, or engagement of these structures by tumor. Having a 
"road map" of the liver vasculature aids in a safer dissection 
and isolation of vascular structures in order to gain vascular 
control before commencing parenchymal transection. Prior 
knowledge of the vascular variants also decreases the risk 
for arterial and portal venous devascularization as well as 
venous stasis of the post-operative liver remnant. Whereas 
the hepatic parenchyma has a dual blood supply  
(75% coming from the portal vein and 25% from the hepatic 
artery), the supply of the biliary tree is exclusively arterial 
making it more vulnerable for arterial devascularization 
especially with damage to the more distal vasculature 
where the potential for formation of collaterals is limited. 
Congestion of the parenchyma in the remnant liver, 
bordering the resection line must be prevented by ensuring 
sufficient venous drainage. Not only is function in the 
congested liver decreased, but even the regenerative 
capacity is compromised (59, 60). 
Consensus statement: CE-MR imaging is the most sensitive 
pre-operative imaging modality used in cirrhosis cases, such 
as HCC whereas MDCT (followed by CE-MR imaging) is the 
standard pre-operative imaging modality used in secondary 
liver lesions, such as colorectal cancer. Both MDCT and CE-
MR imaging are used as standard pre-operative imaging 
modality in transplant cases.
Pre-Surgical Functional Assessments
Liver failure is the biggest cause of post-operative 
mortality after liver resection. Therefore, making an accurate 
pre-operative prediction of post-operative liver function 
and regeneration capacity is vital (61-63). In individuals 
with normal liver function undergoing liver resection, such 
as patients with CRCLM, volume-based decisions regarding 
resection are appropriate, with a remnant of 20-30% of the 
original volume usually being sufficient for maintaining 
post-operative function and for sufficient regeneration. 
In patients with parenchymal dysfunction, volume-based 
decision-making alone is obsolete. The worse the liver 
function, the bigger the volume needed for maintaining 
function and allowing sufficient regeneration. In patients 
with homogeneous disease a global liver function test is 
probably enough for the functional analysis. However, in the 
case of inhomogeneous liver disease, a liver function test 
that can quantify function on a segmental level is needed 
for accurate predictions. Previously, liver cirrhosis was the 
most commonly encountered parenchymal disease in liver 
resection patients. The increasing use of pre-operative neo-
adjuvant chemotherapy in resection candidates for CRCLM 
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and the metabolic syndrome-associated liver diseases (non-
alcoholic fatty liver disease [NAFLD] and non-alcoholic 
steatohepatitis [NASH]) in the wake of the obesity epidemy 
add some new challenges (64).
Currently used liver function tests (e.g. analyte 
measurements and clearance tests) measure total liver 
function (65, 66). We know however, that liver function is 
not homogeneous in some chronic liver diseases such as 
primary sclerosing cholangitis, alcoholic cirrhosis, NAFLD 
and NASH. There is also some evidence that function is not 
Table 1. Pre-Surgical Requirements and Optimized Images from Gd-EOB-DTPA MR Imaging and CT 
Pre-Surgery Requirements Reason  Gd-EOB-DTPA-MRI  CT 
Hepatic artery
Origin and course of 
  common, left and right
  hepatic arteries
Accessory left and right
  hepatic arteries 
  and their origins
Roadmap for gaining 
  vascular control 
  during liver resection
Preventing arterial
  devascularization  
  of liver remnant
Left hepatic artery
  arising from left
  gastric artery with its
  typical course in
  fissure of
  ligamentum venosum
Left hepatic artery
  arising from left
  gastric artery with 
  its typical course 
  in fissure of 
  ligamentum venosum 
Portal vein
Anatomy of portal 
  vein branching
Congenital anatomical 
  variations
Roadmap for dissection 
  in hilus
Prevention of ischemia 
  in remnant  
  liver/transplants
Right posterior portal 
  venous branch arising
  as first branch 
  of main portal vein
Right posterior portal
  venous branch arising
  as first branch of 
  main portal vein
Hepatic veins
Configuration of main
  three veins at HV/
  IVC junction
Additional large veins
  joining IVC
Branching patterns
  of veins close to
  hepatectomy planes
Roadmap for dissection 
  around HV/IVC
  junction and exposure 
  of retrohepatic IVC
Optimization of
  venous drainage 
  in segments adjacent 
  to resection plane
Excellent visualization 
  of accessory inferior 
  right hepatic vein during 
  hepatocyte phase 
Biliary duct
Variations of hepatic 
  duct confluence
Variations of 
  intra-hepatic ductal
  system
Roadmap for dissection 
  in hilus
Prevent biliary leak or
  stasis in remnant  
  liver/transplants
Crossover intra-hepatic 
  variant with right
  posterior segmental
  branch draining into
  left hepatic duct 
  (arrowhead). Arrow marks
   gallbladder
Note.— CT = computed tomography, Gd-EOB-DTPA-MRI = gadolinium-ethoxybenzyl-diethylenetriamine magnetic resonance 
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equally distributed in the healthy liver (67-72). 
Dynamic hepatocyte-specific contrast-enhanced MR 
imaging (DHCE-MR imaging) with Gd-EOB-DTPA is based 
on the principle of a dynamic liver function test using 
an imaging modality as sampling method (72). A number 
of quantitative functional parameters such as hepatic 
extraction fraction (HEF), area under the curve, input 
relative blood flow and mean transit time can be calculated 
on a segmental level enabling the calculation of a volume-
function value for each segment. Total and residual liver 
functions can be calculated by adding these values, with 
the added values correcting for eventual regional variation 
in function. HEF, for example, describing the amount 
of Gd-EOB-DTPA which would be eliminated in one pass 
through the liver, is decreased in patients with primary 
biliary cirrhosis, with values decreasing in correlation with 
increasing grade of biliary cirrhosis (73).
Post-Surgical Complications
MR imaging can provide high-level data regarding 
vascular and biliary complications following surgery. Some 
information, such as vessel configurations or crossing 
and susceptibility artifacts from cholecystectomy clips, 
can be discerned equally well on native T2W or CE-T1-
weighted (T1W) scans. However, the extra dimension of 
time is added, using a hepatocyte-specific contrast agent, 
allowing the tracking of the contrast agent in the biliary 
tree (Fig. 7). That can be helpful for diagnosis of post-
surgical biliary complications such as leakage and stenosis 
in bilio-biliary or bilio-enteric anastomosis. Likewise, 
vascular complications can be confidently diagnosed using 
MR imaging, including aneurysm formation, liver infarction 
or post-surgical bleeding.
Consensus statement: CE-MR imaging is the standard 
imaging modality used post-operatively to assess biliary 
complications.
SUMMARY
Gd-EOB-DTPA-enhanced MR imaging has the potential 
to be a "one-stop shop" for evaluation of patients that 
are candidates for hepatic resection, in terms of diagnosis 
of the primary disease, surgical planning and diagnosis 
and assessment of post-operative complications. In an 
extended protocol, DHCE-MR imaging shows promise as 
a method for functional analysis with the possibility of 
segmental functional assessment that might be superior to 
currently available function tests in the prediction of post-
operative liver function. It is envisaged that the consensus 
statements generated during the liver forum, based on 
evidence-based discussions, will improve diagnostic 
accuracy, patient outcomes and contribute to updates of 
clinical guidelines.
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